INTEGRA Biosciences strengthened its market position in 2025

INTEGRA Biosciences reported a successful financial year in 2025, despite exceptional economic and geopolitical challenges. When adjusted for currency effects, the company achieved a solid growth of 3 percent. Business developed particularly well in Europe, where INTEGRA Biosciences recorded high single-digit growth, and sales in local currency also increased in the US.

 

2025 was marked by considerable external pressures. Customs duties on precision instruments shipped from Zizers to the US had a noticeable impact on the cost structure. In addition, strong currency fluctuations and global reluctance to invest in research and development – especially in the US – placed increased demands on the company. Despite this, INTEGRA’s robust business model and consistent implementation of its long-term strategy paid off. "Our resilience in this challenging environment shows that we are strategically well positioned," commented Urs Hartmann, CEO of INTEGRA Biosciences.

 

INTEGRA Biosciences focused on innovation and strategic development in 2025. The SWITCH hybrid pipette brought a new generation of pipettes to market. This unique hybrid pipette combines precise manual control and fast electronic aliquoting in a single device, accelerating routine processes in the laboratory. This pipette and other new products – including MAGFLO™ NGS magnetic beads for NGS size selection and PCR purification – offer customers noticeable efficiency gains in everyday laboratory work.

 

The SWITCH is the world's first hybrid pipette that combines

manual control and electronic efficiency in a single device.

 

Another strategic milestone for the company was its cooperation with CleanNA, which 

deepened through further investment in 2025, strengthening the joint development of reagents for innovative applications in molecular biology. At the same time, the company introduced a new global corporate planning system, creating the basis for further process optimization and efficiency gains.

 

INTEGRA Biosciences is cautiously optimistic about 2026. Measures already implemented enable the company to compensate for customs costs, and the forthcoming launch of several new products should help to offset the effects of the continuing weakening of the US dollar. The company's commitment to promoting young talent is also encouraging, with 23 apprentices currently making important contributions to the future of INTEGRA Biosciences. "Our strength lies in the combination of innovative power, team spirit and long-term thinking," summarized Urs Hartmann. "This means we are well prepared to remain successful in a persistently volatile environment."
 

Visit the INTEGRA Biosciences website to learn more.
 

 

About INTEGRA

INTEGRA Biosciences AG manufactures innovative pipettes and laboratory products and has its headquarters in Zizers (Switzerland) and Hudson (New Hampshire, USA). The company frequently launches new products tai-lored to customer needs and employs around 605 people worldwide—more than 226 of them in Switzerland, in-cluding 23 trainees.

INTEGRA's high-precision laboratory equipment enables customers in research, diagnostics, and quality control to streamline their workflows, thereby accelerating progress in basic research. This contributes to a faster under-standing, cure, and prevention of diseases. INTEGRA stands for innovation, quality, and customer focus.

As a responsible employer, INTEGRA offers attractive jobs that put people first.

 

Further information about INTEGRA Biosciences: www.integra-biosciences.com 

Further information about INTEGRA Holding: www.integra.ch